Neumaier, Felix ORCID: 0000-0002-6376-6391, Zlatopolskiy, Boris D. and Neumaier, Bernd ORCID: 0000-0001-5425-3116 (2020). Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics. Pharmaceutics, 12 (12). BASEL: MDPI. ISSN 1999-4923

Full text not available from this repository.

Abstract

The emergence and global spread of COVID-19, an infectious disease caused by the novel coronavirus SARS-CoV-2, has resulted in a continuing pandemic threat to global health. Nuclear medicine techniques can be used for functional imaging of (patho)physiological processes at the cellular or molecular level and for treatment approaches based on targeted delivery of therapeutic radionuclides. Ongoing development of radiolabeling methods has significantly improved the accessibility of radiopharmaceuticals for in vivo molecular imaging or targeted radionuclide therapy, but their use for biosafety threats such as SARS-CoV-2 is restricted by the contagious nature of these agents. Here, we highlight several potential uses of nuclear medicine in the context of SARS-CoV-2 and COVID-19, many of which could also be performed in laboratories without dedicated containment measures. In addition, we provide a broad overview of experimental or repurposed SARS-CoV-2-targeting drugs and describe how radiolabeled analogs of these compounds could facilitate antiviral drug development and translation to the clinic, reduce the incidence of late-stage failures and possibly provide the basis for radionuclide-based treatment strategies. Based on the continuing threat by emerging coronaviruses and other pathogens, it is anticipated that these applications of nuclear medicine will become a more important part of future antiviral drug development and treatment.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Neumaier, FelixUNSPECIFIEDorcid.org/0000-0002-6376-6391UNSPECIFIED
Zlatopolskiy, Boris D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neumaier, BerndUNSPECIFIEDorcid.org/0000-0001-5425-3116UNSPECIFIED
URN: urn:nbn:de:hbz:38-309489
DOI: 10.3390/pharmaceutics12121247
Journal or Publication Title: Pharmaceutics
Volume: 12
Number: 12
Date: 2020
Publisher: MDPI
Place of Publication: BASEL
ISSN: 1999-4923
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CONVERTING ENZYME 2; POSITRON-EMISSION-TOMOGRAPHY; SARS CORONAVIRUS; RADIONUCLIDE THERAPY; ACTIVE METABOLITE; STEM-CELLS; PET; INHIBITORS; INFECTION; PROTEASEMultiple languages
Pharmacology & PharmacyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/30948

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item